Dr. Maiti is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2017 - 2020- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2014 - 2017
NRS Medical College CalcuttaClass of 2011
Certifications & Licensure
FL State Medical License 2021 - Present
GA State Medical License 2022 - 2026
TX State Medical License 2020 - 2026
AZ State Medical License 2022 - 2025
LA State Medical License 2022 - 2025
MS State Medical License 2022 - 2025
TN State Medical License 2022 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Publications & Presentations
PubMed
- 54 citationsVenetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.Abhishek Maiti, Miguel Franquiz, Farhad Ravandi, Jorge E. Cortes, Elias Jabbour
Acta Haematologica. 2020-04-14 - 24 citationsImpact of frontline treatment approach on outcomes of myeloid blast phase CMLKapil Saxena, Elias Jabbour, Ghayas C. Issa, Koji Sasaki, Farhad Ravandi
Journal of Hematology & Oncology. 2021-06-15 - 10 citationsPhase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.Abhishek Maiti, Jorge E. Cortes, Alessandra Ferrajoli, Zeev Estrov, Gautam Borthakur
Leukemia & Lymphoma. 2017-02-09
Journal Articles
- Secondary SyphilisPriyanka Bhugra, Abhishek Maiti, The New England Journal of Medicine
Lectures
- Clinical value of event-free survival (EFS) in acute myeloid leukemia (AML).2019 ASCO Annual Meeting - 6/1/2019
- Venetoclax (VEN) and tyrosine kinase inhibitor (TKI) combinations in Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) and chronic myeloid leukemia m...2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
MD Anderson Research Highlights: EHA 2024 Special EditionJune 13th, 2024- Acute Myeloid Leukemia Survivor Shows No Signs of Cancer After Clinical TrialMarch 1st, 2022
- Benjamin S. Abella, MD, MPhil, Named as Chair of the Department of Emergency Medicine for the Mount Sinai Health SystemJune 14th, 2024
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
